Drug Trial Radar · NCT06005428
Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
Last checked: Nov 19, 2026Latest source record: May 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
7
Actual
Start
Nov 7, 2023
Primary completion
May 31, 2025
Study completion May 31, 2025
Sponsor
- Lead sponsor
- Cardurion Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 22, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, multicenter, double-blind, sponsor unblinded, placebo-controlled, single-dose clinical study of CRD-4730 to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CRD-4730 when administered as single oral doses to participants with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). The study will have 2 cohorts in which participants with CPVT will participate in a 3-period, randomized 2-sequence study. Each participant will receive 2 different doses of CRD-4730 and 1 dose of matching placebo, with each study drug administered as a single dose.
Conditions
- CPVT1
- Heart Defects, Congenital
- Heart Diseases
- Ventricular Tachycardia
Interventions
CRD-4730Drug
Oral CRD-4730 in capsule form
PlaceboDrug
Placebo to match CRD-4730 in capsule form
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment Emergent Adverse Events (TEAEs)Time frame: Baseline to Day 22
- Changes in Laboratory AssessmentsTime frame: Baseline to Day 15
- Changes in Vital Signs Measurement: Systolic and Diastolic blood pressureTime frame: Baseline to Day 15
- Changes in Vital Signs Measurement: Pulse RateTime frame: Baseline to Day 15
- Changes in Vital Signs Measurement: Respiratory RateTime frame: Baseline to Day 15
- Changes in Vital Signs Measurement: Body TemperatureTime frame: Baseline to Day 15
- Changes in Physical ExamTime frame: Baseline to Day 22
- Changes in Electrocardiogram (ECG) MeasurementsTime frame: Baseline to Day 22
Locations
11 sites in 4 countries. Site status is shown where the registry gives one.
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Cleveland Clinic Children's Hospital
Cleveland, Ohio
Baylor College of Medicine
Houston, Texas
Stollery Children's Hospital University of Alberta
Edmonton, Alberta, Canada
University of British Columbia (UBC) Hospital
Vancouver, British Columbia, Canada
British Columbia Children's Hospital
Vancouver, British Columbia, Canada
University of Western Ontario
London, Ontario, Canada
Hôpital Louis Pradel
Bron, France
Groupe Hospitalier Bichat Claude Bernard
Paris, France
Hôptal Nord Laennec
Nantes, Loire-Atlantique, France
IRCCS Pavia Istituti Clinici Scientifici Maugeri Spa Società Benefit
Pavia, Lombardy, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.